Latest Shareholder Approvals News

Minbos Resources has locked in a US$16 million debt facility from South Africa’s IDC to fund the next phase of its Cabinda Phosphate Fertilizer Plant construction, marking a key milestone for the project’s development.

Rincon Resources has successfully raised $3.1 million to fund an expanded drilling campaign at its promising Telfer South Gold-Copper Project, following the discovery of a significantly larger mineralised zone at the Hasties Prospect.

Australian Bond Exchange Holdings has completed a $0.98 million placement and is proposing attaching options to raise additional funds, pending shareholder approval.

Dreadnought Resources has agreed to acquire 12 tenements adjacent to its Mangaroon project, consolidating a significant rare earth mineralised strike and unlocking new potential for tungsten, copper, and gold in Western Australia.

New Age Exploration appoints seasoned geologist Kirby Johnson as CEO and acquires the promising Wallah Silver Project in NSW, complementing positive drilling results at its Wagyu Gold Project in Pilbara.

Kingfisher Mining has agreed to sell its Gascoyne rare earth elements project to Dreadnought Resources for $2 million in shares plus milestone payments, freeing capital to advance its copper-gold portfolio in New South Wales.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

Magellan Financial Group has announced a landmark merger with Barrenjoey Capital Partners, creating a diversified financial powerhouse valued at over A$1.6 billion. The deal includes a significant share placement and board reshuffle, setting the stage for expanded market influence.

MCS Services Limited has reported a significantly reduced half-year loss and announced plans to sell its Highways Traffic subsidiary, aiming to strengthen its financial position amid ongoing challenges.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Codeifai Limited reported a 26% revenue decline to $598,497 for 2025 alongside a sharp increase in net loss to $6.22 million, driven by strategic investments and market challenges. The company’s pivot to self-service SaaS platforms, including a key acquisition post-year-end, signals a transformative but uncertain path forward.

Keybridge Capital has posted a $6.14 million loss for the half-year ended 31 December 2024, driven by legacy governance issues and significant legal costs. A new board, appointed following court intervention, is now focused on stabilising the company and pursuing recovery actions.